Cart
sales@molnova.com
Roscovitine
CAS No. 186692-46-6
Roscovitine ( CYC-202;CYC 202;CYC202;Seliciclib )
Catalog No. M12883 CAS No. 186692-46-6
A potent and selective CDK inhibitor with IC50 of 0.2 uM, 0.65 uM, and 0.7 uM for CDK5, Cdc2, and CDK2, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 36 | In Stock |
|
| 10MG | 45 | In Stock |
|
| 25MG | 92 | In Stock |
|
| 50MG | 116 | In Stock |
|
| 100MG | 155 | In Stock |
|
| 200MG | 213 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRoscovitine
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent and selective CDK inhibitor with IC50 of 0.2 uM, 0.65 uM, and 0.7 uM for CDK5, Cdc2, and CDK2, respectively.
-
DescriptionA potent and selective CDK inhibitor with IC50 of 0.2 uM, 0.65 uM, and 0.7 uM for CDK5, Cdc2, and CDK2, respectively; weakly inhibits ERK1 and ERK2 (IC50=34 uM and 14 uM), poorly inhibits CDK4/cyclin D1 and CDK6/cyclin D2 (IC50>100 uM); suppresses the proliferation of mammalian cell lines with an average IC50 of 16 uM; significantly inhibits growth of The Ewing's sarcoma family of tumors (ESFT) xenografts.Lung Cancer Phase 2 Clinical
-
SynonymsCYC-202;CYC 202;CYC202;Seliciclib
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCdc2/CyclinB;CDK2/CyclinA;CDK2/CyclinE;CDK5/p35;ERK2
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number186692-46-6
-
Formula Weight354.45
-
Molecular FormulaC19H26N6O
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCC[C@@H](NC1=NC(NCC2=CC=CC=C2)=C3N=CN(C(C)C)C3=N1)CO
-
Chemical Name1-Butanol, 2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-, (2R)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Meijer L, et al. Eur J Biochem. 1997 Jan 15;243(1-2):527-36.
2. Tirado OM, et al. Cancer Res, 2005, 65(20), 9320-9327.
3. Mgbonyebi OP, et al. Cancer Res. 1999 Apr 15;59(8):1903-10.
2. Tirado OM, et al. Cancer Res, 2005, 65(20), 9320-9327.
3. Mgbonyebi OP, et al. Cancer Res. 1999 Apr 15;59(8):1903-10.
molnova catalog
related products
-
AZD-5438
A potent and oral inhibitor of CDK1/2/9 with IC50 of 16/6/20 nM, respectively; also inhibits the kinase activity of p25-Cdk5 (IC50=14 nM) and GSK-3β (IC50=17 nM) in vitro.
-
LY2835219 mesylate
LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
-
VMY-1-103
A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
